Sector News

Roche dumps lead asset from its $725M Seragon buy

April 28, 2017
Life sciences

Back in 2014, Roche spent $725 million upfront on Seragon Pharmaceuticals, but three years down the line, it has now canned work on its leading drug, ARN-810.

In its first-quarter results announced today, the Swiss major quietly announced that the next-gen SERD drug, RG6046, has been “removed from phase 2” in HER negative advanced breast cancer.

No other details were given, but the compound appears to have been removed from the company’s roster of pipeline meds.

Roche paid $725 million (with $1 billion in biobucks) for Seragon, a privately held biotech based in San Diego, California, three years ago.

Roche got access to Seragon’s entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer. ARN-810 had been leading that pack, and was in phase 1 when it was subsumed into Roche.

Other meds from its buyout are still lined up in its pipeline, however, including RG6047 (GDC-0927, or ARN-927).

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.